{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Hematologic", "query": { "condition": "Neoplasms, Hematologic" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7707, "total_pages": 771, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Hematologic&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T05:19:11.996Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07226609", "title": "A Dietary Study for People With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "nutrition counseling and coaching", "type": "OTHER" }, { "name": "dietary guidelines, research dietitian visit", "type": "OTHER" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Frozen pre-prepared meals", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2025-11-04", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226609" }, { "nct_id": "NCT04191187", "title": "Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia", "Myeloproliferative Neoplasm", "Relapsed Large Cell Lymphoma", "Mantle Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Relapsed Small Lymphocytic Lymphoma", "Relapsed Marginal B-cell Lymphoma", "Relapsed Follicular Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2019-12-06", "completion_date": "2024-02-14", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191187" }, { "nct_id": "NCT05831787", "title": "COVID19 OutcomeS in Myeloma and the Impact of VaCcines", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Patient Reported Outcomes", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "ASH Research Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 201, "start_date": "2024-01-23", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 2, "location_summary": "New York, New York • Chapel Hill, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05831787" }, { "nct_id": "NCT06100237", "title": "Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Daratumumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carl Ola Landgren, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-12-04", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06100237" }, { "nct_id": "NCT03901963", "title": "A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 200, "start_date": "2019-04-26", "completion_date": "2026-05-04", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03901963" }, { "nct_id": "NCT06163898", "title": "A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Alnuctamab", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-02-27", "completion_date": "2025-06-03", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 3, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • New York, New York", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06163898" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT05552222", "title": "A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1590, "start_date": "2022-10-25", "completion_date": "2033-10-28", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 67, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552222" }, { "nct_id": "NCT02914977", "title": "Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphocytic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Daunorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tara Lin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-11", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2022-01-14", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 1, "location_summary": "Fairway, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914977" }, { "nct_id": "NCT02092909", "title": "Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "IMO-8400", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idera Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-03", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-07-24T05:19:11.996Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092909" } ] }